{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-164542","form_type":"8-K","ticker":"FNCHQ","cik":"0001733257","company_name":"Finch Therapeutics Group, Inc.","filed_at":"2023-06-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.286979+00:00","generated_at":"2026-06-14T04:05:36.001062+00:00","sec_items":["5.03","5.07","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Finch Therapeutics shareholders approve 1-for-30 reverse stock split; elect two directors","bullets":["Reverse stock split at 1-for-30 ratio approved by 40,212,819 votes for, 717,495 against.","Common stock to begin trading on post-split basis on June 12, 2023 under new CUSIP 31773D200.","Susan Graf and Chris Shumway elected as Class II directors through 2026; Graf 26,097,717 votes for, Shumway 24,013,503.","Annual meeting had 40,934,688 shares present (~85.02% of outstanding)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-164542","json":"https://secwatch.observer/filing/0001193125-23-164542.json","markdown":"https://secwatch.observer/filing/0001193125-23-164542.md","text":"https://secwatch.observer/filing/0001193125-23-164542.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1733257/000119312523164542/0001193125-23-164542-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1733257/000119312523164542/d620811d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T04:05:36.001062+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"60bc3157592ab39f28f91dcc3d60f1a30f576f9e","claim":"Finch Therapeutics Group, Inc.: Reverse stock split of common stock at a ratio of 1-for-30 (effective 2023-06-09).","evidence_excerpt":"On June 9, 2023, Finch Therapeutics Group, Inc. (the “Company”) filed a Certificate of Amendment (the “Charter Amendment”) to its Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) with the Secretary of State of the State of Delaware to effect a reverse stock split of the Company’s issued and outstanding common stock, par value $0.001 (the “Common Stock”), at a ratio of 1-for-30.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1733257/000119312523164542/0001193125-23-164542-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-06-09"}],"fact_type":"governance_change"},{"claim_id":"a4da008916c15c08cc430cb9ca052ceb6ce95ebd","claim":"Finch Therapeutics Group, Inc. shareholders approved Election of two nominees as Class II directors: Susan Graf and Chris Shumway at the 2023-06-08 meeting.","evidence_excerpt":"To elect two nominees as Class II directors: Susan Graf and Chris Shumway, each to hold office until the Annual Meeting of Stockholders in 2026. Nominee Votes For Votes Withheld Broker Non-Votes Susan Graf 26,097,717 4,226,794 10,610,177 Chris Shumway 24,013,503 6,311,008 10,610,177","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1733257/000119312523164542/0001193125-23-164542-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-08"}],"fact_type":"shareholder_vote"},{"claim_id":"ee7ef3ea13bbef36a71b722ff23e9313094e25b2","claim":"Finch Therapeutics Group, Inc. shareholders approved To approve the Charter Amendment to effect a reverse stock split of the Company’s issued and outstanding Common Stock at a ratio of 1-for-30. at the 2023-06-08 meeting.","evidence_excerpt":"To approve the Charter Amendment to effect a reverse stock split of the Company’s issued and outstanding Common Stock at a ratio of 1-for-30. Votes For Votes Against Abstentions Broker Non-Votes 40,212,819 717,495 4,374 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1733257/000119312523164542/0001193125-23-164542-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-08"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}